HGSOC:disease;'While crizotinib is NCCN-compendium listed for the treatment of patients with high-level MET-amplified non-small cell lung cancer, its clinical utility in patients with MET-amplified high-grade serous ovarian cancer is unknown.';'HGSOC:disease';'id';'BiologicalEntity|Disease|DiseaseOrPhenotypicFeature|Entity|NamedThing'
